丹栀逍遥散联合Lucentis对新生血管性青光眼的临床疗效及血管通透因子和IL-6的影响

摘要

Objective:To observe the clinical effects of intravitreal injection of Lucentis combined with Danzhi Xiaoyao Powder oral treatment of neovascular glaucoma , and try to analyze the related mechanism.Methods:A total of 56 cases of neovascular glaucoma (56 eyes) in panzhihua city central hospital from January 2015 to June 2017 were randomly divided into control group and treat-ment group, with 28 cases in each group.The control group received intravitreal injection of Lucentis for treatment , and the treat-ment group was added Danzhi Xiaoyao Powder.The visual acuity, intraocular pressure of two groups of patients with neovasculariza-tion were observed before and after treatment and after 6 months of follow-up, and the serum VPF and IL-6 levels were observed. The differences of curative effect were analyzed.Results:After treatment, intraocular pressure, visual acuity, neovascularization of two groups were better than those before treatment (P＜0.05), and the treatment group was better than the control group (P＜0.05).After 6 months of follow-up, IOP and visual acuity and angiogenesis of the treatment group was better than that of the con -trol group (P＜0.05).The VPF, IL-6 of two groups were detected after treatment and after 6 months of follow-up, and the VPF IL-6 was significantly lower than the control group , with statistical difference ( P＜0.05).Conclusion:Danzhi Xiaoyao Powder combined with intravitreal injection of Lucentis is effective in the treatment of neovascular glaucoma .After combined use with tradi-tional Chinese medicine , the recurrence rate is smaller , and it is worthy of clinical application.The effect of the mechanism may be related to the regulation of VPF and IL-6 levels.%目的:观察玻璃体腔内注射Lucentis联合丹栀逍遥散口服治疗新生血管性青光眼的临床疗效,并尝试对相关机制进行分析.方法:选取2015年1月至2017年6月攀枝花市中心医院收治的新生血管性青光眼患者56例(56眼),用随机数字表法将其分为对照组和观察组,每组28例(28眼),对照组予以玻璃体腔内注射Lucentis治疗,观察组在此基础上予丹栀逍遥散治疗,并观察治疗前后和随访6个月后患者眼压、视力、新生血管情况,并检测血清中血管通透因子(VPF)及IL-6水平,分析其疗效差异.结果:治疗后2组的眼压、视力、新生血管情况均较治疗前改善(P＜0.05),且观察组优于对照组(P＜0.05),且在随访6个月后,观察组的眼压、视力与新生血管情况仍优于对照组(P＜0.05),同时在对2组患者的VPF、IL-6进行检测发现,观察组治疗后和随访6个月后的VPF、IL-6水平均明显低于对照组(P＜0.05).结论:丹栀逍遥散结合玻璃体腔内注射Lucentis是治疗新生血管性青光眼的有效治疗方法,再结合中药使用后,患者复发率更小,其作用机制可能与调控VPF、IL-6的水平有关.